Topical Vitamin D3 may stimulate hair growth and has been used for Alopecia Areata. There is a question about the lack of research on its use for Androgenetic Alopecia (AGA).
The user discusses using Follics FR5, FR10, and FR15, which combine Minoxidil, Adenosine, Procapil, Azelaic acid, and Procyanidin B2, to address hair loss. They have previously used Minoxidil, Finasteride, and Dutasteride with varying success.
A 20-year-old shares positive results after using 0.5 mg dutasteride and 5% minoxidil for three months, noting crown improvement and some hairline regrowth. The user reports no side effects except new hair and clear skin, while others express skepticism and share their own experiences with hair loss treatments.
The conversation discusses using topical cetirizine for hair loss and questions its effectiveness and preparation. A user expresses interest in trying it if it can be dissolved in minoxidil.
Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.
The user has been using Essengen 6+ (a mix of low-dose topical finasteride and minoxidil) for three months, seeing positive results, especially on the crown area. They also use Nizoral for dandruff and dermaroll weekly.
A user shared their 6-month progress using oral dutasteride (0.5mg daily), topical minoxidil (5% once daily), and ketoconazole shampoo (2% weekly) for hair loss, reporting increased libido and no side effects. They chose dutasteride over finasteride due to availability and convenience.
A person with alopecia universalis is considering using Xeljanz but is advised that Olumiant is more effective for their condition. They are under a dermatologist's care and should expect gradual progress, as follicles dormant for 20 years are challenging to reactivate.
Alfatradiol (0.025%) is an effective and safe treatment for androgenetic alopecia in both men and women, increasing anagen hair rates with minimal side effects. Users discuss its cost-effectiveness and ease of use compared to other treatments like finasteride and RU58841, with some combining it with stemoxydine and Minoxidil.
The conversation discusses using nandrolone decanoate as a replacement for testosterone to potentially regrow hair, with OP considering stopping finasteride and testosterone replacement therapy (TRT) to try nandrolone solo. Concerns include maintaining estradiol levels, and some users report mixed results with hair regrowth using this approach.
A 19-year-old started using finasteride and topical minoxidil with a dermaroller after experiencing hair loss since age 14. The shedding phase lasted about two and a half months and has since stabilized.
A 22-year-old has been using minoxidil and finasteride for hair loss with initial success, but later experienced increased shedding and no regrowth. They recently added vitamin D3 supplements and microneedling, which reduced shedding, but are seeking advice on regrowth, with suggestions to try tretinoin with minoxidil and consider dutasteride.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.
A user in the UK reports significant hair growth progress after three months using a topical spray containing Minoxidil, Finasteride, and Tretinoin, applied daily. They recommend the product from e-Surgery, noting no side effects and using Biotin shampoo every two days.
A 22-year-old shared a 3-month update on using oral minoxidil and finasteride for hair loss, showing significant improvement. Users discussed dosages, previous use of topical treatments, and the importance of finasteride.
Clascoterone (Breezula) is anticipated for release in the coming years but is considered too weak for aggressive androgenetic alopecia (AGA). Current treatments like minoxidil, finasteride, and dutasteride are preferred, with some users obtaining clascoterone from the gray market.
Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.
A user shared their hair regrowth progress after using minoxidil 5% twice daily since January 31 and adding oral dutasteride 0.5mg and minoxidil 2mg daily two weeks ago. They also used microneedling occasionally and are seeking opinions on potential further gains.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
The user experienced severe side effects from finasteride and switched to using minoxidil and a derma stamp, seeing positive hair regrowth after initial shedding. They are considering topical finasteride to avoid side effects while maintaining hair health.
Using the "big three" hair loss treatments (Minoxidil, Finasteride, and Ketoconazole) can initially make hair look worse, often causing dryness and a "straw" texture. Adjusting the routine with gentler shampoos and conditioners can improve hair appearance while waiting for the treatments to show results.
The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.
The conversation discusses the lack of clinical studies on cysteine alone for hair loss, with the original poster already using medications like Minoxidil and finasteride. Suggestions include trying 2ddr as a growth stimulant, though concerns about side effects like gas are mentioned.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
The user started finasteride three months ago, initially at 1mg every other day, then adjusted to 1mg on Monday, Wednesday, and Friday due to side effects. The user reports stronger, more voluminous hair with minimal hair fall and no shedding.
The user has been using dutasteride and oral minoxidil for over three years with good results and is seeking additional treatments to improve hair growth by 10-15%. Suggestions include derma stamping, red light therapy, deep massage, caffeinated shampoos, and biotin supplementation.